SCHEMBL15568522

SCHEMBL15568522

NC(=O)c1cccc(-c2c[nH]c(=S)[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.54
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
HDAC8 Q9BY41 1/20 0.44
PARP1 P09874 5/20 0.43
ERN1 O75460 1/20 0.42
BRD4 O60885 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
MCL1 Q07820 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CCNT1 O60563 1/20 0.42
CCND1 P24385 1/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
CDK7 P50613 1/20 0.42
CDK9 P50750 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL638903 0.86 KDM4E (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL31422694 0.75 PARP1 (0.64) PARP1ERN1POLBMAPTL3MBTL1
SCHEMBL2431097 0.75 PARP1 (0.64) PARP1ERN1POLBMAPTL3MBTL1
SCHEMBL3341441 0.73 GFER (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL3344186 0.73 KDM4E (0.61) GFERKDM4EGAAHDAC8BRD4
SCHEMBL3341447 0.73 KDM4E (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL639362 0.73 GFER (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL6999225 0.73 DHODH (0.63) HDAC8PARP1ERN1POLBMAPT
SCHEMBL27083842 0.73 CDC7 (0.57) PARP1ERN1BRD4POLBMAPT
SCHEMBL258911 0.72 GAA (1.00) GFERKDM4EGAAHDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885306-B1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2016-06-01 EP disclosed
EP-2885306-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014026881-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives MAPT, SNCA, PARK7 GFER 3102/4885KDM4E 4876/4885GAA 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.